EPIGENOMICS AG Inactive Instrument
Epigenomics AG Stock Xetra
Equities
DE000A1K0516
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Sales 2024 * | 150K 161K | Sales 2025 * | - | Capitalization | 1.42M 1.52M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | -4.81 x |
| Net cash position 2024 * | 2.14M 2.29M | Net cash position 2025 * | 1.69M 1.82M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.4
x | P/E ratio 2025 * |
-2.42
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.53% | 11.48B | |
| +41.94% | 3.27B | |
| -36.56% | 2.2B | |
| -18.92% | 2.05B | |
| -29.19% | 1.49B | |
| +15.73% | 1.01B | |
| -4.37% | 743M | |
| -37.00% | 413M | |
| -46.73% | 377M |
